INTRODUCTION: Myxopapillary ependymoma (MPE) is a rare tumor in children. The primary treatment is gross total resection (GTR), with no clearly defined role for adjuvant radiation therapy (RT). Published reports, however, suggest that children with MPE present with a more aggressive disease course. The goal of this study was to assess the role of adjuvant RT in pediatric patients with MPE. METHODS: Sixteen patients with MPE seen at Johns Hopkins Hospital (JHH) between November 1984 and December 2010 were retrospectively reviewed. Fifteen of the patients were evaluable with a mean age of 16.8 years (range, 12-21 years). Kaplan-Meier curves and descriptive statistics were used for analysis. RESULTS: All patients received surgery as the initial treatment modality. Surgery consisted of either a GTR or a subtotal resection (STR). The median dose of adjuvant RT was 50.4 Gy (range, 45-54 Gy). All patients receiving RT were treated at the involved site. After a median follow-up of 7.2 years (range, 0.75-26.4 years), all patients were alive with stable disease. Local control at 5 and 10 years was 62.5% and 30%, respectively, for surgery alone versus 100% at both time points for surgery and adjuvant RT. Fifty percent of the patients receiving surgery alone had local failure. All patients receiving STR alone had local failure compared to 33% of patients receiving GTR alone. One patient in the surgery and adjuvant RT group developed a distant site of recurrence 1 year from diagnosis. No late toxicity was reported at last follow-up, and neurologic symptoms either improved or remained stable following surgery with or without RT. CONCLUSIONS: Adjuvant RT improved local control compared to surgery alone and should be considered after surgical resection in pediatric patients with MPE.
INTRODUCTION:Myxopapillary ependymoma (MPE) is a rare tumor in children. The primary treatment is gross total resection (GTR), with no clearly defined role for adjuvant radiation therapy (RT). Published reports, however, suggest that children with MPE present with a more aggressive disease course. The goal of this study was to assess the role of adjuvant RT in pediatric patients with MPE. METHODS: Sixteen patients with MPE seen at Johns Hopkins Hospital (JHH) between November 1984 and December 2010 were retrospectively reviewed. Fifteen of the patients were evaluable with a mean age of 16.8 years (range, 12-21 years). Kaplan-Meier curves and descriptive statistics were used for analysis. RESULTS: All patients received surgery as the initial treatment modality. Surgery consisted of either a GTR or a subtotal resection (STR). The median dose of adjuvant RT was 50.4 Gy (range, 45-54 Gy). All patients receiving RT were treated at the involved site. After a median follow-up of 7.2 years (range, 0.75-26.4 years), all patients were alive with stable disease. Local control at 5 and 10 years was 62.5% and 30%, respectively, for surgery alone versus 100% at both time points for surgery and adjuvant RT. Fifty percent of the patients receiving surgery alone had local failure. All patients receiving STR alone had local failure compared to 33% of patients receiving GTR alone. One patient in the surgery and adjuvant RT group developed a distant site of recurrence 1 year from diagnosis. No late toxicity was reported at last follow-up, and neurologic symptoms either improved or remained stable following surgery with or without RT. CONCLUSIONS: Adjuvant RT improved local control compared to surgery alone and should be considered after surgical resection in pediatric patients with MPE.
Authors: S E Schild; K Nisi; B W Scheithauer; W W Wong; M K Lyons; P J Schomberg; E G Shaw Journal: Int J Radiat Oncol Biol Phys Date: 1998-12-01 Impact factor: 7.038
Authors: Daniel R Gomez; Brian T Missett; William M Wara; Kathleen R Lamborn; Michael D Prados; Susan Chang; Mitchel S Berger; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2005-07 Impact factor: 12.300
Authors: Samuel T Chao; Taisei Kobayashi; Edward Benzel; Chandana A Reddy; Glen H J Stevens; Richard A Prayson; Iain Kalfas; Richard Schlenk; Ajit Krishnaney; Michael P Steinmetz; William Bingaman; Joseph Hahn; John H Suh Journal: J Neurosurg Spine Date: 2010-12-03
Authors: J N Waldron; N J Laperriere; L Jaakkimainen; W J Simpson; D Payne; M Milosevic; C S Wong Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: Michael Safaee; Michael C Oh; Joseph M Kim; Derick Aranda; Phiroz E Tarapore; Tene A Cage; Nalin Gupta; Andrew T Parsa Journal: Childs Nerv Syst Date: 2013-05-16 Impact factor: 1.475
Authors: John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289
Authors: Pratiti Bandopadhayay; V Michelle Silvera; Pedro D S C Ciarlini; Hayley Malkin; Wenya Linda Bi; Guillaume Bergthold; Ahmed M Faisal; Nicole J Ullrich; Karen Marcus; R Michael Scott; Rameen Beroukhim; Peter E Manley; Susan N Chi; Keith L Ligon; Liliana C Goumnerova; Mark W Kieran Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130
Authors: Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal Journal: Neuro Oncol Date: 2018-03-27 Impact factor: 12.300